Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769162 | 1.00 | GPR119 (0.57) | GPR119USP30SPRPIK3CDEPHX2 | |
| SCHEMBL30193463 | 1.00 | GPR119 (0.57) | GPR119USP30SPRPIK3CDEPHX2 | |
| SCHEMBL6305698 | 0.93 | GPR119 (0.53) | GPR119USP30SPRALDH1A1HTT | |
| SCHEMBL639943 | 0.93 | GPR119 (0.63) | GPR119USP30SPREPHX2ALDH1A1 | |
| SCHEMBL6306297 | 0.90 | GPR119 (0.53) | GPR119USP30SPREPHX2 | |
| SCHEMBL29548089 | 0.90 | GPR119 (0.53) | GPR119USP30SPREPHX2 | |
| SCHEMBL7466419 | 0.88 | GPR119 (0.54) | GPR119USP30SPRPIK3CD | |
| SCHEMBL12526598 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD | |
| SCHEMBL13128900 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD | |
| SCHEMBL18756989 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348490-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230348490-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| EP-4186910-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116178391-A | Forward allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-109310668-B | Positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2023-01-24 | — | — | CN | disclosed |
| US-20230014109-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-01-19 | — | — | US | disclosed |
| EP-3534901-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11142532-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-11008335-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200181166-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| US-20190161498-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2019-05-30 | — | — | US | disclosed |
| US-10239887-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170369505-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2017-12-28 | — | — | US | disclosed |
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014109-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
| US-20230348490-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | GPR119 2332/4885USP30 3488/4885SPR 1477/4885 |
| US-11008335-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | GPR119 175/4885USP30 2697/4885SPR 1165/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | GPR119 2038/4885USP30 3406/4885SPR 1748/4885 |
| US-11142532-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
| US-20200181166-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | GPR119 175/4885USP30 2697/4885SPR 1165/4885 |
| US-20190161498-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
| US-20170369505-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
| US-10239887-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | GPR119 220/4885USP30 2974/4885SPR 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.